BioAge Labs Discontinues Clinical Trial for Obesity Treatment

Dow Jones

2024/12/07

By Sabela Ojea

BioAge Labs said it is discontinuing a Phase 2 clinical trial evaluating its drug azelaprag to treat obesity.

The clinical-stage biopharmaceutical company on Friday said it is also discontinuing the trial for the combination of azelaprag with tirzepatide after some subjects receiving azelaprag were diagnosed with liver transaminitis.

No transaminase elevations were observed in the tirzepatide only treatment group, the company added.

"While this outcome is a significant disappointment, we remain encouraged by azelaprag's promising preclinical and Ph1b efficacy profile," Chief Executive Kristen Fortney said.

The trial of azelaprag and in combination with tirzepatide was expected to enroll around 220 individuals with obesity aged 55 years and older.

Write to Sabela Ojea at sabela.ojea@wsj.com

(END) Dow Jones Newswires

December 06, 2024 17:15 ET (22:15 GMT)

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2489243262"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2489243262\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2489243262?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-07 06:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2489243262","market":"us","top_or_hot":-1,"title":"BioAge Labs Discontinues Clinical Trial for Obesity Treatment","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Sabela Ojea \n</p>\n<pre>\n \n</pre>\n<p>\n  BioAge Labs said it is discontinuing a Phase 2 clinical trial evaluating its drug azelaprag to treat obesity. \n</p>\n<p>\n  The clinical-stage biopharmaceutical company on Friday said it is also discontinuing the trial for the combination of azelaprag with tirzepatide after some subjects receiving azelaprag were diagnosed with liver transaminitis. \n</p>\n<p>\n  No transaminase elevations were observed in the tirzepatide only treatment group, the company added. \n</p>\n<p>\n  \"While this outcome is a significant disappointment, we remain encouraged by azelaprag's promising preclinical and Ph1b efficacy profile,\" Chief Executive Kristen Fortney said. \n</p>\n<p>\n  The trial of azelaprag and in combination with tirzepatide was expected to enroll around 220 individuals with obesity aged 55 years and older. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Sabela Ojea at sabela.ojea@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 06, 2024 17:15 ET (22:15 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BioAge Labs Discontinues Clinical Trial for Obesity Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioAge Labs Discontinues Clinical Trial for Obesity Treatment\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2024-12-07 06:15</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Sabela Ojea \n</p>\n<pre>\n \n</pre>\n<p>\n  BioAge Labs said it is discontinuing a Phase 2 clinical trial evaluating its drug azelaprag to treat obesity. \n</p>\n<p>\n  The clinical-stage biopharmaceutical company on Friday said it is also discontinuing the trial for the combination of azelaprag with tirzepatide after some subjects receiving azelaprag were diagnosed with liver transaminitis. \n</p>\n<p>\n  No transaminase elevations were observed in the tirzepatide only treatment group, the company added. \n</p>\n<p>\n  \"While this outcome is a significant disappointment, we remain encouraged by azelaprag's promising preclinical and Ph1b efficacy profile,\" Chief Executive Kristen Fortney said. \n</p>\n<p>\n  The trial of azelaprag and in combination with tirzepatide was expected to enroll around 220 individuals with obesity aged 55 years and older. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Sabela Ojea at sabela.ojea@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 06, 2024 17:15 ET (22:15 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"製藥","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2489243262","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2489243262","pubTimestamp":1733523300,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"BioAge Labs said it is discontinuing a Phase 2 clinical trial evaluating its drug azelaprag to treat obesity.The clinical-stage biopharmaceutical company on Friday said it is also discontinuing the trial for the combination of azelaprag with tirzepatide after some subjects receiving azelaprag were diagnosed with liver transaminitis.No transaminase elevations were observed in the tirzepatide only treatment group, the company added.\"While this outcome is a significant disappointment, we remain encouraged by azelaprag's promising preclinical and Ph1b efficacy profile,\" Chief Executive Kristen Fortney said.The trial of azelaprag and in combination with tirzepatide was expected to enroll around 220 individuals with obesity aged 55 years and older.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","BIOA":"BioAge Labs Inc."},"translate_title":"BioAge Labs停止肥胖治疗临床试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BIOA":1},"content_text":"By Sabela Ojea \n\n\n \n\n\n  BioAge Labs said it is discontinuing a Phase 2 clinical trial evaluating its drug azelaprag to treat obesity. \n\n\n  The clinical-stage biopharmaceutical company on Friday said it is also discontinuing the trial for the combination of azelaprag with tirzepatide after some subjects receiving azelaprag were diagnosed with liver transaminitis. \n\n\n  No transaminase elevations were observed in the tirzepatide only treatment group, the company added. \n\n\n  \"While this outcome is a significant disappointment, we remain encouraged by azelaprag's promising preclinical and Ph1b efficacy profile,\" Chief Executive Kristen Fortney said. \n\n\n  The trial of azelaprag and in combination with tirzepatide was expected to enroll around 220 individuals with obesity aged 55 years and older. \n\n\n \n\n\n  Write to Sabela Ojea at sabela.ojea@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 06, 2024 17:15 ET (22:15 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}